Stock Analysis

Dna Group (T.R.) Full Year 2024 Earnings: EPS: ₪0.18 (vs ₪0.01 loss in FY 2023)

TASE:DNA
Source: Shutterstock
Advertisement

Dna Group (T.R.) (TLV:DNA) Full Year 2024 Results

Key Financial Results

  • Net income: ₪23.4m (up from ₪1.18m loss in FY 2023).
  • EPS: ₪0.18 (up from ₪0.01 loss in FY 2023).
earnings-and-revenue-history
TASE:DNA Earnings and Revenue History March 17th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Dna Group (T.R.) shares are down 4.9% from a week ago.

Risk Analysis

You should learn about the 4 warning signs we've spotted with Dna Group (T.R.) (including 3 which are concerning).

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About TASE:DNA

Dna Group (T.R.)

Engages in the development, manufacturing, and marketing of patented ultrasound systems in Israel, North America, East Asia, and internationally.

Flawless balance sheet and fair value.

Advertisement